Respiratory system diseases

The therapeutic area of respiratory diseases includes diseases such as asthma, chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). In this area, the G-BA has assessed 20 medicinal products in 33 procedures. The G-BA has found a major additional benefit for 0% and a considerable additional benefit for 6.6% of the subpopulations weighted according to patient shares in the respective resolution and in relation to the comparative therapy. The G-BA has identified a minor additional benefit for 21.6% and a non-quantifiable additional benefit for another 3.1%%. No additional benefit was shown for 68.4% of the subpopulations and less benefit has been identified for a further % in relation to the comparative therapy. According to resolutions by the G-BA, 73% of the maximum of the 27.1 million patients treatable with the evaluated medicinal products do not benefit from these medicinal products.